ORTHOPEDIATRICS CORP

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $37.3m
$45.6m +22.31%
$57.6m +26.17%
$72.6m +26.05%
$71.1m -2.03%
$98.0m +37.95%
$122.3m +24.72%
$148.7m +21.62%
$204.7m +37.65%
$236.3m +15.45%
$252.7m +6.93%
Cost of Revenue $10.9m
$11.2m +2.19%
$14.9m +33.21%
$17.9m +20.53%
$16.0m -10.52%
$24.6m +53.59%
$31.6m +28.33%
$37.5m +18.50%
$56.1m +49.76%
$63.7m +13.47%
$66.6m +4.56%
Gross Profit $26.4m
$34.5m +30.66%
$42.7m +23.89%
$54.6m +27.97%
$55.0m +0.75%
$73.4m +33.38%
$90.7m +23.51%
$111.3m +22.71%
$148.6m +33.57%
$172.7m +16.19%
$186.1m +7.80%
Interest Income (Expense), Net ($2.2m)
($2.4m) -7.88%
$198k +108.17%
$2.6m +1223.74%
$6.0m +128.77%
Research and Development Expense $2.2m $3.4m $4.7m $5.7m $5.3m $5.5m $8.0m $10.2m $11.0m $9.1m $9.1m
Selling and Marketing Expense $16.7m $20.5m $26.6m $31.3m $31.9m $39.7m $45.1m $51.4m $64.3m $72.7m $199.8m
General and Administrative Expense $11.6m $17.0m $20.9m $26.7m $38.3m $46.1m $59.4m $75.4m $102.8m $119.8m $122.9m
Amortization of Intangible Assets $35k $246k $378k $887k $3.2m $4.5m $6.0m $7.1m $7.8m $8.2m
Operating Expenses $32.5m $40.9m $52.2m $63.7m $81.8m $91.4m $116.1m $138.0m $183.6m $211.9m $208.9m
Operating Income (Loss) ($6.1m)
($6.5m) -5.63%
($9.6m) -47.61%
($9.1m) +4.98%
($26.8m) -194.76%
($18.0m) +32.63%
($25.4m) -40.92%
($26.8m) -5.32%
($35.0m) -30.87%
($39.2m) -12.08%
($22.8m) +41.96%
Interest Expense $1.5m $2.5m $2.3m $3.5m $3.4m $6.0m
Interest Expense, Debt $42k $35k $27k $6.0m
Other Nonoperating Income (Expense) $1.0m $30k ($217k) ($70k) $20k $1.1m ($1.8m) $2.3m ($1.1m) $6.0m
Interest Expense (non-operating) $2.6m $6.0m $6.0m
Income (Loss) from Continuing Operations before Income Taxes, Domestic ($12.0m) ($28.8m) ($9.2m) $6.5m ($12.6m) ($27.3m) ($37.1m) ($39.4m)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $12.7m $33.7m ($17.4m) ($3.7m) ($21.3m) ($41.9m) ($39.2m) ($39.4m)
Current Income Tax Expense (Benefit) $0 $0 $723k $1.1m $85k $825k $629k $613k $278k
Income Tax Expense (Benefit) $0 $0 $0 $0 ($723k) ($1.1m) ($4.9m) ($338k) ($4.1m) $460k $278k
Net Income (Loss) Attributable to Parent ($6.6m)
($8.9m) -35.91%
($12.0m) -34.63%
($13.7m) -14.19%
($32.9m) -139.92%
($16.3m) +50.64%
$1.3m +107.74%
($21.0m) -1767.25%
($37.8m) -80.33%
($39.6m) -4.83%
($39.7m) -0.20%
Net Income (Loss) Available to Common Stockholders, Basic ($12.4m)
($23.5m) -89.03%
($12.0m) +48.90%
($13.7m) -14.19%
($32.9m) -139.92%
$1.2m
($21.0m) -1798.30%
($37.8m) -80.33%
($39.6m) -4.83%
($39.7m) -0.20%
Earnings Per Share, Basic ($7.14) ($5.86) ($0.96) ($0.94) ($1.82) ($0.84) $0.06 ($0.92) ($1.64) ($1.69) ($1.68)
Earnings Per Share, Diluted ($7.14) ($5.86) ($0.96) ($0.94) ($1.82) ($0.84) $0.06 ($0.92) ($1.64) ($1.69) ($1.68)
Income (Loss) from Continuing Operations, Per Basic Share ($7.14) ($5.86) ($0.96) ($1) ($2) ($1) $0 ($1) ($2) ($2)
Income (Loss) from Continuing Operations, Per Diluted Share ($7.14) ($5.86) ($0.96) ($1) ($2) ($1) $0 ($1) ($2) ($2)
Weighted Average Number of Shares Outstanding, Basic 19.3m 20.7m 22.7m 23.1m 23.5m 23.7m
Weighted Average Number of Shares Outstanding, Diluted 19.3m 20.9m 22.7m 23.1m 23.5m 23.7m
Additional Financial Items
Business Combination, Acquisition Related Costs $737k
Goodwill, Impairment Loss $0 $0 $0 $1.9m $4.6m
Realized Investment Gains (Losses) ($1.6m) ($1.4m) $119k $32k
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($6.6m) ($8.9m) ($12.0m) ($12.7m) ($32.9m) ($16.3m) $1.3m ($21.0m) ($37.8m) ($39.6m)
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($16.3m)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $0 $0 ($1.0m) $0 $0